Funded Projects

Project # Project Title Research Focus Area Research Program Administering IC(s) Institution(s) Investigator(s) Location(s) Year Awarded
1R41AR080620-01A1
Injectable Ice Slurry Cooling Technology for Treatment of Postoperative Pain Cross-Cutting Research Small Business Programs NIAMS BRIXTON BIOSCIENCES, INC. SIDOTI, CHARLES Cambridge, MA 2022
FOA Title: HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R41/R42 Clinical Trial Not Allowed)
FOA Number: RFA-NS-20-009
Summary:

More than 700,000 total knee replacement surgeries are performed each year in the United States to relieve joint pain in patients with end-stage osteoarthritis or rheumatic arthritis. However, many patients still experience significant pain after this procedure, calling for additional long-lasting, drug-free pain management strategies. This project will develop and test a commercial prototype device for persistent knee pain after total knee replacement. The injection-based method freezes peripheral nerves to reduce pain sensation.

1R61AT012187-01
Total-Body PET for Assessing Myofascial Pain Clinical Research in Pain Management Discovery and Validation of Novel Targets for Safe and Effective Treatment of Pain NCCIH UNIVERSITY OF CALIFORNIA AT DAVIS CHAUDHARI, ABHIJIT J Davis, CA 2022
FOA Title: HEAL Initiative: Developing Quantitative Imaging and Other Relevant Biomarkers of Myofascial Tissues for Clinical Pain Management
FOA Number: RFA-AT-22-003
Summary:

Myofascial pain syndrome is a prevalent and debilitating condition and can aggravate other conditions such as sickle cell disease. This project will use total body imaging using positron emission tomography/computed tomography (TB-PET/CT) to identify and monitor this pain syndrome and potential treatments over time. The research will use TB-PET/CT to assess myofascial tissue effects of chronic low back pain and sickle cell disease pain. The first phase of the project will assess health changes observed by TB-PET/CT imaging in painful and non-painful myofascial tissues compared to healthy myofascial tissue. The second phase of the research will be a randomized, controlled longitudinal interventional study to evaluate the effectiveness of acupuncture on myofascial pain syndrome, using TB-PET/CT imaging to assess changes.

1UG3DA056247-01
Phase 1 and 2 Studies of Sublingual Dexmedetomidine, an Alpha 2 Adrenergic Agonist, for Treating Opioid Withdrawal Novel Therapeutic Options for Opioid Use Disorder and Overdose Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose NIDA NEW YORK STATE PSYCHIATRIC INSTITUTE dba RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC LEVIN, FRANCES RUDNICK New York, NY 2022
FOA Title: Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trial Optional)
FOA Number: PAR-20-092
Summary:

Withdrawal symptoms associated with current opioid use disorder treatments, such as naltrexone or buprenorphine, can be serious obstacles to successful treatment. This project aims to develop a U.S. Food and Drug Administration-approved sedative medication (dexmedetomidine) as an under-the-tongue film to treat opioid withdrawal symptoms at doses that have minimal ill effects on blood pressure and heart rate. This research will compare the safety and efficacy of dexmedetomidine to lofexidine, which is currently approved to treat opioid withdrawal.

1R21CA277849-01
The Effects of Hydrocodone Rescheduling on Pain Management of Older Lung Cancer Patients Cross-Cutting Research Leveraging Existing and Real-Time Opioid and Pain Management Data NCI PENNSYLVANIA STATE UNIV HERSHEY MED CTR SHEN, CHA Hershey, PA 2022
FOA Title: HEAL Initiative: Secondary Analysis and Integration of Existing Data Related to Acute and Chronic Pain Development or Managementin Humans (R21 Clinical Trials Not Allowed)
FOA Number: RFA-DE-22-011
Summary:

Pain is common, complex, and debilitating in many cancer patients. Although adequate pain management can significantly improve health-related quality of life for these individuals, substantial disparities limit care access, especially among underserved populations. After the 2014 Drug Enforcement Agency policy that raised the risk potential of the opioid hydrocodone (from Schedule III to Schedule II), few studies examined the impact of this policy on pain management strategies and outcomes among cancer patients. This project will use national cancer registry data linked with Medicare claims to assess the change in opioid and non-opioid medication use among older lung cancer patients before and after this policy change. By focusing on older racial/ethnic minority groups dually eligible for both Medicare and Medicaid, the research will also examine disparities in the use of medications for pain management and service use consistent with inadequate pain management.

1R44NS125745-01A1
Development and Evaluation of Computerized Chemosensory-Based Orbitofrontal Networks Training for Treatment of Pain (CBOT-P) Cross-Cutting Research Small Business Programs NINDS EVON MEDICS, LLC NWAOKOBIA, CHARLES CHIEDU Elkridge, MD 2022
FOA Title: HEAL INITIATIVE: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 - Clinical Trial Required)
FOA Number: RFA-NS-20-010
Summary:

Research shows that individuals with chronic pain may experience brain changes that contribute to anxiety, depression, and cognitive impairment. This project will test a user-friendly, home-based device to treat chronic pain. The device stimulates the brain through olfactory training: repetitive daily stimulation with specific smells. The research will optimize a treatment approach and test the device in a clinical study.

3UH3AR076387-02S2
Fibromyalgia TENS in Physical Therapy Study (TIPS): An Embedded Pragmatic Clinical Trial Cross-Cutting Research Increasing Participant Diversity, Inclusion, and Engagement in HEAL Research NIAMS UNIVERSITY OF IOWA SLUKA, KATHLEEN A Iowa City, IA 2022
FOA Title: HEAL Initiative: Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements to Support Strategies to Increase Participant Diversity, Inclusion and Engagement in Clinical Studies
FOA Number: NOT-NS-22-066
Summary:

Fibromyalgia is a chronic pain condition characterized by widespread musculoskeletal pain, tenderness, stiffness, fatigue, and sleep disturbance. The FAST trial (Fibromyalgia Activity Study with transcutaneous electrical nerve stimulation [TENS]) was the first study to conclusively demonstrate the clinical value of TENS for treating musculoskeletal pain. While physical therapists are trained in the use of TENS, it is underused in clinical practice. This project will test TENS in fibromyalgia patients receiving physical therapy in a real-world physical therapy practice setting. This research will determine if adding TENS to physical therapy reduces pain, increases adherence to physical therapy and allows fibromyalgia patients to reach their self-defined functional goals with less use of medication.

1R43CA268700-01A1
Pre-clinical Validation of Phase II Peptide LRP-1 Agonist to Treat and Prevent Chemotherapy Induced Peripheral Neuropathy Cross-Cutting Research Small Business Programs NCI SERPIN PHARMA, LLC GINESTE, CYRILLE Manassas, VA 2022
FOA Title: HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 – Clinical Trial Not Allowed)
FOA Number: RFA-NS-20-011
Summary:

Some chemotherapy treatments damage nerves outside the brain and spinal cord. This condition, chemotherapy-induced peripheral neuropathy, involves tingling, burning, weakness, or numbness in hands and/or feet and affects nearly 70% of cancer patients receiving chemotherapy. Common pain medications, including opioids, can relieve pain for short intervals but are not suitable for long-term therapy. This project will develop and test a new type of treatment (reduced size cyclic analogs) for this condition. The research will evaluate the ability of this therapy to reduce inflammation and pain, as well as to repair nerve damage.

1R21AG082344-01
Using Secondary Analyses to Test Novel Pathways Linking Family Stress and Pain Incidence and Persistence Among African Americans Cross-Cutting Research Leveraging Existing and Real-Time Opioid and Pain Management Data NIA UT SOUTHWESTERN MEDICAL CENTER WOODS, SARAH B Dallas, TX 2022
FOA Title: HEAL Initiative: Secondary Analysis and Integration of Existing Data Related to Acute and Chronic Pain Development or Managementin Humans (R21 Clinical Trials Not Allowed)
FOA Number: RFA-DE-22-011
Summary:

Chronic pain is a persistent source of disability and reduced quality of life for aging adults. Chronic pain-related outcomes are disproportionately worse for aging African Americans, who report greater pain severity and worse pain-related disability compared to White peers. A significant pain risk factor for African Americans is chronic stress (including family-related stress), which is worsened by structural inequities that affect this population. Although many African Americans identify family support as critical for pain self-management, this influence has not been studied thoroughly. This project will study how pain conditions develop and persist for aging African Americans by analyzing existing data from African American participants in two large aging studies: Midlife in the U.S. (721 participants) and the Health and Retirement Study (2,698 participants). The research aims to determine how family emotional climate affects pain risk, taking into account structural factors like discrimination, socioeconomic disparity, and the influence of various neighborhood settings.

1R44CA271904-01A1
Novel Biologic to Treat Chemotherapy-Induced Neuropathic Pain Cross-Cutting Research Small Business Programs NCI RAFT PHARMACEUTICALS, LLC KOGAN, YAKOV San Diego, CA 2022
FOA Title: HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 – Clinical Trial Not Allowed)
FOA Number: RFA-NS-20-011
Summary:

Some chemotherapy treatments damage nerves outside the brain and spinal cord. This condition, chemotherapy-induced peripheral neuropathy, involves tingling, burning, weakness, or numbness in hands and/or feet and affects nearly 70% of cancer patients receiving chemotherapy. Common pain medications, including opioids, can relieve pain for short intervals but are not suitable for long-term therapy. This project will conduct studies to investigate the safety and tolerability of a novel strategy to treat neuropathic pain: modifying the activity of the dorsal root ganglia, which are nerve cells in the spinal cord that communicate pain signals to and from the brain.

3UH3AR076729-02S1
The Spine Phenome Project: Enhancing Patient Diversity Cross-Cutting Research Increasing Participant Diversity, Inclusion, and Engagement in HEAL Research NIAMS OHIO STATE UNIVERSITY MARRAS, WILLIAM STEVEN Columbus, OH 2022
FOA Title: HEAL Initiative: Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements to Support Strategies to Increase Participant Diversity, Inclusion and Engagement in Clinical Studies
FOA Number: NOT-NS-22-066
Summary:

Chronic pain is a debilitating medical condition that affects roughly 50 million people in the United States. Current diagnostics and treatments rely primarily on subjective metrics and do not target the unique biological, psychological, and social factors that contribute to an individual’s pain. This project is part of the NIH Back Pain Consortium (BACPAC) program, a patient-centered effort to address the need for effective and personalized therapies for chronic low back pain. This research will enhance patient diversity within the BACPAC research participant population.

1UG3DA053094-01A1
The Development of Delta Opioid Receptor Agonists for the Treatment of Opioid Withdrawal Associated Behaviors Novel Therapeutic Options for Opioid Use Disorder and Overdose Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose NIDA UNIVERSITY OF ILLINOIS AT CHICAGO PRADHAN, AMYNAH AMIR ALI Chicago, IL 2022
FOA Title: Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trial Optional)
FOA Number: PAR-20-092
Summary:

This project aims to develop a new way to stimulate the delta opioid receptor to treat withdrawal and abstinence from chronic opioid use. Withdrawal can cause pain, depression, and anxiety, which contribute to relapse. The research will test promising drug candidates in animal models with the intention of bringing at least one effective and safe compound to the final stage of drug development before human clinical trials can begin.

1R01DA057630-01
Predicting Fatal and Non-Fatal Overdose in Los Angeles County with Rapid Overdose Surveillance Dashboard to Target Street-Based Addiction Treatment and Harm Reduction Services Cross-Cutting Research Leveraging Existing and Real-Time Opioid and Pain Management Data NIDA UNIVERSITY OF CALIFORNIA LOS ANGELES SHOVER, CHELSEA LEIGH; GOODMAN, DAVID Los Angeles, CA 2022
FOA Title: HEAL Initiative: Data and Methods to Address Urgent Needs to Stem the Opioid Epidemic (R01- Clinical Trial Not Allowed)
FOA Number: RFA-DA-22-044
Summary:

Effective overdose prevention requires timely, location-specific data to efficiently direct resources and interventions as well as to inform healthcare policy. However, rarely is such information available, resulting in responses that are frequently too late. This project will partner with local government agencies from Los Angeles County, California, to rapidly acquire and analyze information in near real-time from multiple sources to identify overdose hotspots and determine overdose metrics. This information will be used to develop a publicly available Rapid Overdose Surveillance Los Angeles online dashboard with built-in analytics. The dashboard will help determine the scope and specifics of overdose and opioid use in Los Angeles County to help target response and guide mobile addiction treatment and harm reduction services.

1R01DA057654-01
Expansion of Mail-Delivered Harm Reduction Services in the U.S. Translation of Research to Practice for the Treatment of Opioid Addiction Harm Reduction Approaches to Reduce Overdose Deaths NIDA WEILL MEDICAL COLL OF CORNELL UNIV BEHRENDS, CZARINA NAVOS New York, NY 2022
FOA Title: HEAL Initiative: Harm Reduction Policies, Practices, and Modes of Delivery for Persons with Substance Use Disorders (R01 Clinical Trial Optional)
FOA Number: RFA-DA-22-046
1R01DA057633-01
Teaching Harm Reduction in Vulnerable Environments (THRIVE): A Peer-Led Intervention Bridging Acute Care Settings and the Discharge to the Community Translation of Research to Practice for the Treatment of Opioid Addiction Harm Reduction Approaches to Reduce Overdose Deaths NIDA UNIVERSITY OF PITTSBURGH WILSON, JACQUELINE DEANNA Pittsburgh, PA 2022
FOA Title: HEAL Initiative: Harm Reduction Policies, Practices, and Modes of Delivery for Persons with Substance Use Disorders (R01 Clinical Trial Optional)
FOA Number: RFA-DA-22-046
1R61DA057600-01
Using Data to Drive Action to Reduce Opioid Overdoses in Seattle, WA Cross-Cutting Research Translating Data 2 Action to Prevent Overdose NIDA UNIVERSITY OF WASHINGTON BANTA-GREEN, CALEB; HOOD, JULIA Seattle, WA 2022
FOA Title: HEAL Initiative: HEAL Data2Action Innovation Projects (R61/R33 Clinical Trial Optional)
FOA Number: RFA-DA-22-051
Summary:

This project will use a data-to-action framework to guide implementation of opioid use disorder treatment and harm reduction interventions based on rapid data analysis. It will leverage existing data systems such as Emergency Medical Services (EMS) reports, mobile integrated health case management data, and medical examiner data for near real-time data analyses, visualization, and action planning. This research will collect a range of data (opioid treatment, use of acute care services, morbidity, mortality, incarceration, housing support, and cost benefits) from a sub-acute stabilization center for people at high risk for opioid overdose, including those who have recently overdosed and are referred and transported by EMS teams.

1R01DA057685-01
Identifying Suspected Drug Overdose Deaths in Near Real-Time Using Data Collected by Death Investigators Cross-Cutting Research Leveraging Existing and Real-Time Opioid and Pain Management Data NIDA FRIENDS RESEARCH INSTITUTE, INC. HOCHSTATTER, KARLI RAE Baltimore, MD 2022
FOA Title: HEAL Initiative: Data and Methods to Address Urgent Needs to Stem the Opioid Epidemic (R01- Clinical Trial Not Allowed)
FOA Number: RFA-DA-22-044
Summary:

Effective responses to the highly dynamic overdose crisis require accurate and timely information about the timing and location of drug overdoses, which is currently reported mainly through death certificates that take time to become available and thus limit life-saving responses. This project will comprehensively evaluate, optimize, and assess barriers and facilitators to adoption of a surveillance tool developed by the New York City Office of the Chief Medical Examiner. The tool uses data routinely collected during death investigations to predict in near real-time whether a death was due to an unintentional drug overdose. The findings will inform drug overdose mortality surveillance efforts in other states.

1R01DA057613-01
Assessing the Reach, Effectiveness, and Implementation of Multiple Harm Reduction Interventions Translation of Research to Practice for the Treatment of Opioid Addiction Harm Reduction Approaches to Reduce Overdose Deaths NIDA RESEARCH TRIANGLE INSTITUTE KRAL, ALEXANDER H Research Triangle Park, NC 2022
FOA Title: HEAL Initiative: Harm Reduction Policies, Practices, and Modes of Delivery for Persons with Substance Use Disorders (R01 Clinical Trial Optional)
FOA Number: RFA-DA-22-046
3U2COD023375-07S1
ACT-NOW Data Sustainability - ECHO Administrative Supplement Cross-Cutting Research Leveraging Existing and Real-Time Opioid and Pain Management Data OD/ECHO DUKE UNIVERSITY SMITH, PHILLIP BRIAN; NEWBY, LAURA KRISTIN Durham, NC 2022
FOA Title: Notice of Special Interest (NOSI): Availability of Administrative Supplements for Helping to End Addiction Long-term (HEAL) Initiative awardees to make data Findable, Accessible, Interoperable, and Reusable (FAIR) through the HEAL Data Ecosystem
FOA Number: NOT-OD-22-110
Summary:

This research provides support to strengthen data management, data sharing, and data readiness efforts within the HEAL Initiative. This support further fosters collaboration among HEAL awardees and enables maximal data discoverability, interoperability, and reuse by aligning with the FAIR (Findable, Accessible, Interoperable, and Reusable) principles. It also provides an opportunity for existing HEAL Initiative award recipients to increase data “FAIR”-ness, participate in coordinated HEAL Initiative activities to build community around data sharing, and foster sustainability of HEAL Initiative digital assets.

1U24DA057612-01
WF DISC: Navigating Data Solutions for Chronic Pain and Opioid Use Disorder Cross-Cutting Research Translating Data 2 Action to Prevent Overdose NIDA WAKE FOREST UNIVERSITY HEALTH SCIENCES ADAMS, MEREDITH C B Winston-Salem, NC 2022
FOA Title: HEAL Initiative: HEAL Data2Action Data Infrastructure Support Center (U24 Clinical Trial Optional)
FOA Number: RFA-DA-22-052
Summary:

This project creates the HEAL Data2Action Data Infrastructure Support Center that will conduct research as well as support the HEAL Data2Action Innovation Projects with analytics and support for navigating electronic health records and other “big data” sources, as well as logistical processes related to privacy and ethics. The center will help plan for data collection and assessing outcomes, as well as provide data visualization efforts for various stakeholders. Key support mechanisms include courses, seminars, conferences, trainings, and on-demand technical assistance.

1R21DA057598-01
Tracking the Opioid Epidemic with Social Media: An Early Warning System Cross-Cutting Research Leveraging Existing and Real-Time Opioid and Pain Management Data NIDA STANFORD UNIVERSITY ALTMAN, RUSS BIAGIO Redwood City, CA 2022
FOA Title: HEAL Initiative: Exploratory Data and Methods to Address Urgent Needs to Stem the Opioid Epidemic (R21- Clinical Trial Not Allowed)
FOA Number: RFA-DA-22-045
Summary:

A key component to addressing the current opioid overdose crisis is the ability to track dangerous opioid use in a timely manner so that public health agencies can plan accordingly. Direct reports about drug use and overdoses from social media might provide a useful early warning system that when combined with other sources, can provide policy makers and public health officials with powerful tools for monitoring this public health crisis. This project will explore the usefulness of Twitter and Reddit as a social media component of opioid use surveillance – in particular by monitoring mentions of fentanyl and synthetic opioids at various geographic levels (e.g., local or regional) and over time.

1R01DA057682-01
A Network-Based, Mixed Methods Study to Identify and Support Multiple Overdose Responders and Inform Overdose Prevention Interventions Translation of Research to Practice for the Treatment of Opioid Addiction Harm Reduction Approaches to Reduce Overdose Deaths NIDA UNIVERSITY OF NEVADA RENO WAGNER, KARLA D Reno, NV 2022
FOA Title: HEAL Initiative: Harm Reduction Policies, Practices, and Modes of Delivery for Persons with Substance Use Disorders (R01 Clinical Trial Optional)
FOA Number: RFA-DA-22-046
1R01DA057658-01
Weighting Longitudinal Data to Access Opioid Analgesia Tapering Outcomes Among Patients with Co-Occurring Chronic Pain and Substance Use Disorder Cross-Cutting Research Leveraging Existing and Real-Time Opioid and Pain Management Data NIDA LOYOLA UNIVERSITY CHICAGO QEADAN, FARES Maywood, IL 2022
FOA Title: HEAL Initiative: Data and Methods to Address Urgent Needs to Stem the Opioid Epidemic (R01- Clinical Trial Not Allowed)
FOA Number: RFA-DA-22-044
Summary:

Guidelines published by the Centers for Disease Control and Prevention in 2016 recommended gradual reductions in opioid medication doses (opioid tapering) for people with chronic pain and substance use disorder and recommended that those patients with pain and opioid use disorder should be switched to opioid use disorder medications. Despite wide implementation, little is known about the consequences of opioid tapering among patients with co-occurring chronic pain and substance use disorder. This project will use various databases (Cerner Real-World DataTM, American Hospital Association data, and U.S. Census data) to create a representative electronic health records database. This database will be used to determine the relationship between opioid tapering, multidisciplinary pain treatment, and medications for opioid use disorder – as well as monitor outcomes for patients with chronic pain and co-occurring substance use disorder.

1R01DA057651-01
Culturally Response Integrated Harm Reduction Services for Black and Latinx People Who use Drugs Translation of Research to Practice for the Treatment of Opioid Addiction Harm Reduction Approaches to Reduce Overdose Deaths NIDA NEW YORK UNIVERSITY SCHOOL OF MEDICINE JORDAN, AYANA New York, NY 2022
FOA Title: HEAL Initiative: Harm Reduction Policies, Practices, and Modes of Delivery for Persons with Substance Use Disorders (R01 Clinical Trial Optional)
FOA Number: RFA-DA-22-046
1R24DA057611-01
RTI HEAL Harm Reduction Network Coordination Center Translation of Research to Practice for the Treatment of Opioid Addiction Harm Reduction Approaches to Reduce Overdose Deaths NIDA RESEARCH TRIANGLE INSTITUTE OGA, EMMANUEL AJA; CANCE, JESSICA DUNCAN Research Triangle Park, NC 2022
FOA Title: HEAL Initiative: Harm Reduction Policies, Practices, and Modes of Delivery for Persons with Substance Use Disorders: Coordination Center (R24 Clinical Trial Optional)
FOA Number: RFA-DA-22-042
1U2CDA057717-01
HD2A Research Adoption Support Center (RASC) Cross-Cutting Research Translating Data 2 Action to Prevent Overdose NIDA STANFORD UNIVERSITY MCGOVERN, MARK P; BECKER, SARA J; BECKER, WILLIAM C; BROWN, C HENDRICKS Redwood City, CA 2022
FOA Title: HEAL Initiative: HEAL Data2Action Research Adoption Support Center (U2C Clinical Trial Optional)
FOA Number: RFA-DA-22-050
Summary:

This project creates the HEAL Data2Action Research Adoption Support Center to support the HEAL Data2Action Innovation Projects. It will provide supportive evidence for prevention and treatment practices, form implementation strategies, assess outcomes, obtain feedback from the projects, and assess readiness for scalability. This center will offer on-demand technical assistance, host a learning collaborative, harmonize dissemination and implementation data, provide implementation support, and help with stakeholder engagement. The research will also catalogue evidence-based and emerging opioid use disorder and pain management practices as a resource to the field. The center will address timely, high-priority implementation challenges.